- Home
- WLGS vs NLSP Comparison
WLGS vs NLSP Comparison
Compare WLGS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- NLSP
- Stock Information
- Founded
- WLGS 1981
- NLSP 2015
- Country
- WLGS Hong Kong
- NLSP Switzerland
- Employees
- WLGS N/A
- NLSP N/A
- Industry
- WLGS Engineering & Construction
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- NLSP Health Care
- Exchange
- WLGS Nasdaq
- NLSP Nasdaq
- Market Cap
- WLGS 4.4M
- NLSP 12.4M
- IPO Year
- WLGS 2023
- NLSP 2021
- Fundamental
- Price
- WLGS $0.04
- NLSP $2.13
- Analyst Decision
- WLGS
- NLSP
- Analyst Count
- WLGS 0
- NLSP 0
- Target Price
- WLGS N/A
- NLSP N/A
- AVG Volume (30 Days)
- WLGS 66.9M
- NLSP 268.4K
- Earning Date
- WLGS 08-14-2025
- NLSP 07-22-2025
- Dividend Yield
- WLGS N/A
- NLSP N/A
- EPS Growth
- WLGS N/A
- NLSP N/A
- EPS
- WLGS N/A
- NLSP N/A
- Revenue
- WLGS $3,951,649.00
- NLSP N/A
- Revenue This Year
- WLGS N/A
- NLSP N/A
- Revenue Next Year
- WLGS N/A
- NLSP N/A
- P/E Ratio
- WLGS N/A
- NLSP N/A
- Revenue Growth
- WLGS N/A
- NLSP N/A
- 52 Week Low
- WLGS $0.03
- NLSP $1.30
- 52 Week High
- WLGS $9.66
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- WLGS 32.09
- NLSP 43.58
- Support Level
- WLGS $0.04
- NLSP $2.20
- Resistance Level
- WLGS $0.08
- NLSP $2.33
- Average True Range (ATR)
- WLGS 0.01
- NLSP 0.25
- MACD
- WLGS 0.01
- NLSP -0.07
- Stochastic Oscillator
- WLGS 27.27
- NLSP 6.86
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.